Subcutaneous Tumor Implantation
Subcutaneous Tumor Implantation - Related Videos
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
0 Views •
Cited by 15 •
2015
This protocol describes a method for the detailed evaluation of leukocyte subsets within the tumor microenvironment in a mouse tumor model. Chemerin-expressing B16 melanoma cells were implanted subcutaneously into syngeneic mice. Cells from the tumor microenvironment were then stained and analyzed by flow cytometry, allowing for detailed leukocyte subset analyses.
02:43
Tumor Implantation and Injection of a Tumor Vaccine in a Mouse Model
0 Views •
2025
This video demonstrates a cell-based tumor vaccination assay. A mouse, intradermally injected with B16-F10 melanoma cells for tumor formation, is vaccinated with B16-F10 cells secreting Flt3L cytokine near the developed tumor. The secreted Flt3L from the vaccine promotes the maturation and proliferation of dendritic cells that then present tumor antigens to T cells in lymph nodes, triggering a targeted anti-tumor immune response.
04:13
An Adjuvant Therapy in a Mouse Model with an Incompletely Resected Subcutaneous Tumor
0 Views •
2025
This video illustrates testing of adjuvant or additional therapy in a mouse model with incompletely resected subcutaneous tumors. The partially tumor-resected mouse is treated with an antibody targeting the anti-cytotoxic protein of T regulatory cells, potentially reducing tumor regrowth and suggesting effective adjuvant therapy.
03:44
A Unique Mouse Model for Quantitative Assessment of Biofilm Formation on Surgical Implants in Subcutaneous Abscess
0 Views •
Cited by 1 •
2025
This protocol describes a unique experimental model of implant-related infections that enables the simultaneous incubation of two implants with bacteria under identical conditions within a single mouse. It also allows precise assessment of biofilm formation on implant surfaces using optimized comparative analytical methods, demonstrating advanced techniques for evaluating biomaterials' antimicrobial properties.
08:38
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
0 Views •
Cited by 13 •
2013
We describe the manufacture of compressed hormone pellets, as well as subcutaneous surgical implantation into mice. This strategy can be combined with the growth of cell and tissue xenografts under the renal capsule of athymic nude mice to evaluate hormonal carcinogenesis and regulation of benign prostate growth.
FAQs
After placement beneath the skin, tumor cells or tissue can proliferate and interact with the surrounding tissue. As the mass develops, it may also establish a blood supply that supports continued growth. These combined processes allow investigators to observe how implanted tumors develop in vivo and to examine biological responses alongside changes in tumor size.
The subcutaneous location makes the resulting tumor mass relatively easy to monitor through palpation or measurement. This accessibility supports repeated assessment of growth and treatment response without relying only on endpoint observations. As a result, researchers can connect changes in the visible or measurable mass with experimental interventions during a preclinical study.
Subcutaneous tumor implantation can provide information about more than simple mass expansion. The model reflects tumor-cell proliferation, interactions between the tumor and surrounding tissue, and development of a blood supply. Considering these features helps researchers interpret growth patterns and treatment effects as outcomes of tumor biology within a living system.
A typical workflow begins by placing tumor cells or tumor tissue beneath the skin. After implantation, the developing mass is followed using palpation or measurement, while investigators assess its growth and response to treatment. The straightforward sequence supports reproducible preclinical experiments in which tumor development can be linked to planned therapeutic testing.
The approach supports xenograft, syngeneic, and patient-derived tumor studies. Using these different tumor sources allows cancer researchers to examine tumor growth and treatment response across several experimental contexts. The choice of model can therefore align the implantation study with the biological question, whether the focus is drug evaluation, tumor behavior, or translational research.
Researchers can use the model to test individual anticancer drugs and therapeutic combinations by comparing tumor growth and treatment response in vivo. Its reproducible setup and accessible tumor location make outcomes easier to monitor during the experiment. Findings can then help connect laboratory observations with treatment effects measured in a living cancer model.